<DOC>
	<DOCNO>NCT01290692</DOCNO>
	<brief_summary>TVI-Brain-1 experimental treatment take advantage fact body produce immune cell , call 'killer ' white blood cell ability kill large number cancer cell present body . TVI-Brain-1 design generate large number 'killer ' white blood cell deliver cell body kill cancer cell .</brief_summary>
	<brief_title>Study To Test Safety Efficacy TVI-Brain-1 As A Treatment Recurrent Grade IV Glioma</brief_title>
	<detailed_description>The TVI-Brain-1 treatment involve several step . First , patient 's cancer surgically remove provide cell vaccine . Second , patient vaccinate vaccine formulation . Third , patient 's blood filter killer T cell precursor culture stimulated reach high ( killer ) activity level . Fourth , activate cell infused patient 's bloodstream able attack cancer .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age &gt; 18 Informed consent Diagnosis grade IV glioma progression follow standard treatment . Must able tolerate surgery provide tumor tissue vaccine . Must able produce viable vaccine tumor tissue . Karnofsky Performance Status must 70 great . Negative HIV test . Negative hepatitis B C virus . Respiratory reserve must reasonable . Sufficient renal function . Satisfactory blood count . Negative pregnancy test woman childbearing potential . Surgically remove cancer reveals grade IV glioma . Concomitant lifethreatening disease . Active autoimmune disease . Currently receive chemotherapy biological therapy treatment cancer . Currently receive immunosuppressive drug reason . Prior treatment Avastin antiangiogenesis treatment within 6 month . Prior treatment Gliadel wafer . Corticosteroids beyond perioperative period . Psychological , familial , sociological geographical condition permit adequate medical followup compliance study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Brain Neoplasms</keyword>
	<keyword>Central Nervous System Neoplasms</keyword>
	<keyword>Brain Diseases</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Nervous System Neoplasms</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Astrocytoma</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Glioma</keyword>
	<keyword>Recurrent astrocytoma</keyword>
	<keyword>Recurrent glioma</keyword>
	<keyword>Cancer vaccine</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Killer T cell</keyword>
	<keyword>Activated T cell</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>Activated lymphocyte</keyword>
</DOC>